Navigation Links
Histogen Announces Start of Hair Regrowth Clinical Evaluation
Date:11/20/2008

Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today announced the start of the Company's first human clinical evaluation of ReGenica for hair regrowth. ReGenica is the first naturally stabilized and bioactive formulation of wnt proteins and natural cofactors, which are thought to act in the formation of new hair follicles.

San Diego, CA (PRWEB) November 20, 2008 -- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today announced the start of the Company's first human clinical evaluation of ReGenicaTM for hair regrowth. The primary objective of the study is to evaluate safety in the clinical application of the ReGenica product.

ReGenica is a proprietary liquid formula created by the culturing of newborn fibroblasts in an embryonic-like environment, and then harvesting the naturally secreted growth factors, anitoxidants and other synergistic bioproducts that are produced. It is the first naturally stabilized and bioactive formulation of wnt proteins and natural cofactors, which are thought to act in the formation of new hair follicles.

Histogen's in-vitro and preclinical research to date has shown ReGenica to be safe, and has indicated the complex's ability to increase hair growth and new follicle formation. Based on the results of preliminary research, and the potential of ReGenica as a hair regrowth treatment, Histogen has moved forward with this outside-U.S. study to more rapidly obtain human safety data which will allow the Company to progress with product development.

"We are excited to be on schedule with the initiation of our first human clinical evaluation of ReGenica for hair growth," said Dr. Gail Naughton, CEO and Chairman of the Board for Histogen. "We look forward to the results of this preliminary safety evaluat
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit
2. Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market
3. Recognized Dermatology Expert Dr. Zoe Draelos Joins Histogen Scientific Advisory Board
4. Dr. Gail Naughton Speaks on Histogen's Business Plan and the Rise of Bioaesthetic Medicine during Commercial Translation of Regenerative Medicine
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... is the device," Nobel laureate Herbert Kroemer famously ... found at the junctures where layers of different ... the interfaces between layers of metal oxides are ... favorites as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. ...
(Date:1/15/2014)... Look inside the new Preferred Solutions® catalog ... from fluid handling to instruments to supplies. Many items ... order. , Preferred Solutions features a full selection ... model for precise flow control and dispensing to I/P® ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... , KALAMAZOO, Mich., Nov. 3 Tolera Therapeutics, Inc., ... application with the United States Food and Drug Administration ... acute rejection of solid organ transplantation. TOL101 is ... and specifically target T cells, components of the immune ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 3 Poniard Pharmaceuticals, ... oncology, today reported financial results for the third quarter ended ... "During the third quarter, we reached the 320th event target ... picoplatin for the treatment of small cell lung cancer. ...
... November 3 The new market research,report, ,Global ... 2014),published by MarketsandMarkets ( http://www.marketsandmarkets.com ) analyzes,the major ... identifies and analyzes,the main market drivers, restraints, and ... submarkets in different,geographic regions. , ...
Cached Biology Technology:Tolera Therapeutics Files IND Application for TOL101, Appoints O'Toole to Lead Clinical Operations 2Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 7MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 3
(Date:4/23/2014)... transformed the energy landscape in the U.S., but ... among the energy industry, residents and agricultural interests ... that degraded water quality is a potential risk ... appears in the ACS journal Environmental Science ... colleagues point out that a major criticism of ...
(Date:4/23/2014)... from using triclosan as an antimicrobial ingredient in soaps, ... scientists are reporting new evidence that appears to support ... Chemical Research in Toxicology , found that triclosan, ... the growth of human breast cancer cells in lab ... Choi and colleagues note that hormonal imbalances seem to ...
(Date:4/23/2014)... today announced Sophie Martin of the University of Lausanne, ... Medal. The award acknowledges her work to understand the ... the cell. , Martin has been working for the ... the way in which the spatial organization of cells ... last 11 years, she has been using fission yeast, ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2EMBO Gold Medal 2014 awarded to Sophie Martin 2
... block CNS infectionA single molecular anchor that allows bacteria to ... many types of bacterial meningitis, a University of California, San ... By blocking the molecule's anchoring ability, researchers may be able ... serious infection of the central nervous system and a major ...
... cruel disease. Left untreated, prostate cancer cells often metastasize, ... that are extremely painful. , More than 80 ... with metastatic disease in their bones. But scientists know ... up housekeeping in bone tissue and produce the dense ...
... this webpage for pictures and videos! , With ... sea lilies look a lot like their garden-variety namesakes. Perhaps ... lilies stayed rooted instead of moving around like their stalkless ... a submersible research vessel at a depth of 430 meters ...
Cached Biology News:Researchers identify molecular anchor that allows bacterial invasion of central nervous system 2Researchers identify molecular anchor that allows bacterial invasion of central nervous system 3Prostate cancer uses Wnt signaling proteins to promote growth of bone tumors 2Prostate cancer uses Wnt signaling proteins to promote growth of bone tumors 3U. of Colorado researcher identifies tracks of swimming dinosaur in Wyoming 2U. of Colorado researcher identifies tracks of swimming dinosaur in Wyoming 3
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
MAb to IgG2 (Fc gamma-2) IgG2 (Fc, gamma-2 epitope)...
... formulated for non-denaturing polyacrylamide and agarose gel ... solution contains a bromophenol blue tracking dye ... sample loading. EDTA has been included to ... SDS has been added to help dissociate ...
... Polyclonal Antibody Description: ... polyclonal antibody. Detects 70 kDa YAP ... blotting and immunohistochemistry. ... Storage: -20C ...
Biology Products: